CHARLES RIVER LABORATORIES INTERNATIONAL, INC. vs UL Solutions Inc., two Biotechnology stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where CRL and ULS diverge most: on net margin, CRL reads -4.6% and ULS reads 11.3%; on return on equity, CRL reads -6.3% and ULS reads 26.2%. The rest of the comparable metrics sit closer together. What CRL's price implies is a demanding bet versus history and the cohort (whole-company basis). What ULS's price implies is a somewhat stretched bet versus history (segment-resolved basis). The bull and bear cases for each are in their full reports below.
| Metric | CRL | ULS |
|---|---|---|
| Price | $233.67 | $87.26 |
| Market cap | $11.4B | $17.8B |
| Sector | Biotechnology | Biotechnology |
| Stage | Mature | Mature |
| P/E | — | 50.7 |
| P/B | 3.88 | 13.32 |
| P/S | 2.84 | 5.73 |
| EV/EBITDA | 26.8 | 29.9 |
| Revenue growth | +0.1% | +6.9% |
| Operating margin | 12.0% | 18.2% |
| Net margin | -4.6% | 11.3% |
| Return on equity | -6.3% | 26.2% |
| Return on assets | -2.4% | 11.8% |
| Return on invested capital | 1.9% | 24.5% |
| FCF yield | 3.4% | 2.5% |
| Dividend yield | — | 0.6% |
| Debt / equity | 0.00 | 0.27 |
| Current ratio | 1.36 | 1.16 |
| Altman Z (solvency) | 2.33 | 7.52 |
| Piotroski F (quality) | 6 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.